Chinese Society of Hematology Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2017
NCT03335943
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Chinese Society of Hematology

Active Ingredients

Drugs in Phase 4 Trials (1)

cda-2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 4)

Preleukemia (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1